Hoster et al proposed the Mantle Cell Lymphoma (MCL) International Prognostic Index (MIPI). The authors are from multiple hospitals in Europe, the German Low Grade Lymphoma Study Group (GLSG) and the European Mantle Cell Lymphoma Network.
Patient selection: treatment-naive advanced-stage mantle cell lymphoma (Ann Arbor Stage III or IV)
Parameters:
(1) age of the patient in years
(2) ECOG status (0 if ECOG 0 or 1, 1 if ECOG 2 or more)
(3) ratio of serum LDH to the upper limit of the normal reference range
(4) WBC count in 10^9/L
prognostic score =
= (0.03535 * (age in years)) + (0.6978 * (points for ECOG score)) + (1.367 * LOG10((serum LDH)/(upper limit reference range serum LDH))) + (0.9393 * LOG10(WBC count))
where:
• The units for serum LDH do not matter because a ratio is calculated.
Prognostic Score |
Risk |
Overall Survival at 5 Years |
< 5.7 |
low |
60% |
5.7 to 6.1999 |
intermediate |
40% |
>= 6.2 |
high |
17% |
Purpose: To evaluate a patient with advanced-stage mantle cell lymphoma (MCL) using the MCL International Prognostic Index (MIPI) of Hoster et al.
Specialty: Hematology Oncology
Objective: severity, prognosis, stage
ICD-10: C83.1,